Mechanical and biological prostheses (comparison)Bioprosthetic and mechanical valves in the elderly: Benefits and risks**
References (9)
- et al.
Ten year experience with aortic valve replacement in 482 patients 70 years of age or older: operative risk and long-term results
Ann Thorac Surg
(1990) - et al.
Durability of porcine valves at fifteen years in a representative North American patient population
J Thorac Cardiovasc Surg
(1992) - et al.
Carpentier-Edwards standard porcine bioprosthesis: primary tissue failure (structural valve deterioration) by age groups
Ann Thorac Surg
(1988) - et al.
Aortic valve replacement with the Hancock standard, Björk-Shiley Lillehei-Kaster prostheses. A comparison on follow-up from 1 to 15 years
J Thorac Cardiovasc Surg
(1989)
Cited by (64)
Age-related cardiovascular changes and diseases
2022, Cardiovascular PathologyMitral Valve Replacement Using Carpentier-Edwards Pericardial Bioprosthesis in Patients With Rheumatic Heart Disease Aged Below 40 Years: 17-Year Results
2018, Heart Lung and CirculationCitation Excerpt :There still exists a controversy regarding the use of anticoagulant therapy after valve replacement with a bioprosthesis [5,6,8,16]. In this study, the anticoagulation medicines were stopped after 12 weeks in most of the patients with a comparable low rate of thromboembolism of 0.32 events per 100 patient years [5,6,8,16]. This occurrence rate is comparable with Akins (1% per patient-year) whereas he and other authors performed anticoagulant therapy continuously in the majority of MVR patients [18].
Age-related Cardiovascular Changes and Diseases
2016, Cardiovascular Pathology: Fourth EditionPredictors of Survival and Modes of Failure After Mitroflow Aortic Valve Replacement in 1,003 Adults
2015, Annals of Thoracic SurgeryVery late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25-year follow-up of 450 implantations
2014, Journal of Thoracic and Cardiovascular SurgeryCitation Excerpt :Holper and colleagues26 reported a 15-year actuarial freedom from hemorrhage of 88% ± 4% with a bioprosthesis and 57% ± 11% with a mechanical valve. In the present study, despite the relatively large number of patients (65%) who received oral anticoagulation, the rate of major bleeding (0.7%/valve-year; 20-year actuarial freedom, 80.2% ± 10.8%) was lower than that observed in patients receiving a mechanical prosthesis.26,29,30 This could be explained by the different international normalized ratio targets: 2 to 3 for a bioprosthesis with atrial fibrillation compared with 3 to 4.5 for mechanical valves.
Quality of Life After Implantation of Bileaflet Prostheses in Elderly Patients: An Anticoagulation Work Group Experience
2007, Annals of Thoracic Surgery
- **
Presented at the VI International Symposium for Cardiac Bioprostheses, Vancouver, BC, Canada, July 29–31, 1994.